Table 2.

Epidermal growth factor receptor tyrosine kinase inhibitor trials in adult malignant gliomas

Author	Agent	Phase	N	Histology	Newly Dx vs Progression
de Groot et al121	Erlotinib Carboplatin	II	44	GBM	Progression
Brown et al122	Erlotinib Temozolomide RT	I/II	97	GBM	Newly Dx
Prados et al118	Erlotinib Temozolomide	I	83	GBM,AA,AO,AOA	Progression
Haas-Kogan et al14	Erlotinib Temozolomide	I	41	GBM,AA,AO, GA,A, O	Progression
Schwer et al124	Gefitinib SRS	I	15	GBM,AA	Progression
Franceshi et al120	Gefitinib	II	28	GBM,AA,AO	Progression
Rich et al125	Gefitinib	II	57	GBM	Progression
Reardon et al126	Gefitinib Sirolimus	I	34	GBM,AA	Progression
Prados et al127	Gefitinib Temozolomide	I	28	GBM,AA,AOA,AO	Progression
Preusser et al119	Erlotinib Gefitinib	II	21	GBM,AA,AOA	Progression
Lassman et al117	Erlotinib Gefitinib	I/II	33	GBM,AA,AOA	Progression
Doherty et al29	Erlotinib Gefitinib Sirolimus	I	28	GBM,AG	Progression
Mellinghoff et al13	Erlotinib Gefitinib Temozolomide		82	GBM,AO	Progression

Abbreviations: GBM, glioblastoma multiforme (gliosarcoma subjects are also included under this heading); AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; A, astrocytoma; Dx, diagnosis; O, oligodendroglioma; GA, gemistocytic astrocytoma; AG, anaplastic glioma (nonspecified); RT, radiation therapy; SRS, stereotactic radiosurgery.